Qilu Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Study of QL1706 in Subjects With Advanced Malignant Tumor
- Conditions
- Advanced Malignant Tumor
- Interventions
- Biological: QL1706
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT04296994
- Locations
- 🇨🇳
Sun Yat-sen Univeisity Cancer Center, Guangzhou, Guangdong, China
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04234594
- Locations
- 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: QL1203Drug: PlaceboDrug: mFOLFOX6 regimen
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 590
- Registration Number
- NCT04233151
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04213105
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04157257
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of jilin university, Changchun, Jilin, China
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: TDF tabletDrug: QL-007
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04157699
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of Jilin university, Changchun, Jilin, China
Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: PlacebosDrug: QL1206
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT04128163
- Locations
- 🇨🇳
Shanghai sixth people's hospital, Shanghai, Shanghai, China
A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: QL-007 tabletDrug: TDF
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03770624
- Locations
- 🇨🇳
Peking University First Hospital, Peking, Beijing, China
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT03651947
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03557580
- Locations
- 🇨🇳
Qingyuan People's Hospital, Qingyuan, China